Metabolomics Shared Resource

代谢组学共享资源

• 批准号: 9572511
• 负责人: Wei Jia
• 金额: $ 13.52万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9572511
• 关键词: Address; Analytical Chemistry; Area; Big Data; Bioinformatics; Biological; Biological Assay; Biological Markers; Cancer Center; Cancer Center Support Grant; Cell Line; Clinical; Complex; Consultations; Core Facility; Coupled; DNA Sequence Alteration; Data; Data Analyses; Data Set; Detection; Development; Diet; Disease; Educational workshop; Ensure; Evaluation; Exposure to; Feasibility Studies; Hawaii; Health; Individual; Informatics; Intervention; Investments; Life Style; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Metabolic; Methods; Monitor; Natural Products; Outcome; Pathway interactions; Pharmaceutical Preparations; Pharmacology; Plasma; Preparation; Property; Quality Control; Reproducibility; Research; Research Infrastructure; Research Personnel; Resource Sharing; Sampling; Schedule; Services; Smoking; Statistical Data Interpretation; Technical Expertise; Technology; Training; Training and Education; Tumor Tissue; United States National Institutes of Health; Universities; Urine; Validation; analytical method; anticancer research; base; biomarker panel; data archive; design; disorder risk; experience; in vitro Model; instrument; instrumentation; member; metabolic profile; metabolome; metabolomics; method development; pollutant; programs; quality assurance; statistics

ABSTRACT The Metabolomics Shared Resource (MeSR) provides UHCC members and researchers with premium access to expert advice, consultation and technical support services to enable use of advanced metabolomics and bioinformatics technologies for studies spanning the entire range of cancer research areas represented in the center. Research conducted by UHCC investigators requires measurements of endogenous metabolites to discover associations with biological outcomes or disease risk and ensure the consistency and relevance of in vitro models. These studies span various genetic mutations, “lifestyle” exposures (diet, smoking), and natural product interventions. Measurement of a large panel of metabolites or metabolite markers in biological samples requires sophisticated instrumentation and technical expertise. Mass spectroscopic (MS)-based metabolic profiling approaches have been increasingly applied to in an attempt to understand how metabolome of mammalian biofluids (serum/plasma or urine), tumor tissues, cell lines (lysates) alter as a result of metabolic transformation in cancer. Challenges remain in the application of MS metabolic profiling to routine cellular, clinical and biomedical studies. Our overall hypothesis is that an MS-based, high-throughput metabolomics platform can identify and characterize metabolite markers and mechanistic pathways that are implicated in cancer development or treatment. The properties of the target metabolites at low concentration levels in biological samples frequently present unique challenges for sample preparation and analysis. With validated metabolomics methods offered in the lab, the omics data analysis can also be challenging, particularly since biological and health outcomes are dictated by exposures to drugs or multiple agents often requiring simultaneous measurements of multi-panel biomarkers of a cancer or a treatment and integrated informatics and statistical analysis of the resulting "big data” sets. MeSR addresses these challenges through the following Specific Aims: 1) provide consultation in the design and execution of studies that require use of metabolomics platform technologies for cancer research; 2) provide expertise in method development including sample preparation to enable detection and quantitation of low-concentration or volatile metabolites in complex samples; 3) provide consultation and practical assistance with statistical and informatics methods for the analysis of metabolomics datasets generated using the services described in the preceding aims; and 4) provide education and training in metabolomics methods for cancer research. MeSR is operated by experienced professional staff with effective mechanisms in place for technical oversight, control and monitoring of instrument scheduling and access, data archiving and analysis, quality control and quality assurance. The lab has sufficient capacity to accommodate new research initiated from UHCC research programs; effective use of these facilities by researchers often requires new method development, initial feasibility studies, and assay validation.

摘要 代谢组学共享资源(MeSR)为UCC成员和研究人员提供溢价 获得专家咨询、咨询和技术支持服务，以使用先进的代谢组学 和生物信息学技术，用于跨越下列癌症研究领域的全部研究 在中心。UHCC调查人员进行的研究需要测量内源性代谢物以 发现与生物学结果或疾病风险的关联，并确保 体外模型。这些研究涵盖了各种基因突变、“生活方式”暴露(饮食、吸烟)和自然环境。 产品干预。生物样品中大量代谢物或代谢物标志物的测定 需要精密的仪器和技术专长。基于质谱仪(MS)的代谢 谱分析方法已经越来越多地被应用于试图理解新陈代谢组是如何 哺乳动物体液(血清/血浆或尿液)、肿瘤组织、细胞系(裂解物)因代谢而改变 癌症的转化。MS代谢谱在常规细胞、临床应用中的挑战依然存在 和生物医学研究。我们的总体假设是，基于MS的高通量代谢组学平台可以 识别和表征与癌症有关的代谢物标记物和机制途径 发展或治疗。低浓度生物体内靶代谢产物的性质 样品常常对样品的制备和分析提出独特的挑战。经过验证的代谢组学 在实验室中提供的方法，组学数据分析也可能是具有挑战性的，特别是因为生物学和 健康结果取决于接触药物或多种药物，通常需要同时使用 癌症或治疗的多组生物标志物的测量以及综合信息学和统计学 对由此产生的“大数据”集合的分析。MESR通过以下具体目标应对这些挑战： 1)为需要使用代谢组学平台的研究的设计和执行提供咨询 癌症研究技术；2)提供方法开发方面的专业知识，包括样品制备 能够检测和定量复杂样品中的低浓度或挥发性代谢物；3)提供 为代谢组学分析提供统计和信息学方法的咨询和实际援助 使用上述目标中描述的服务生成的数据集；以及4)在以下方面提供教育和培训 用于癌症研究的代谢组学方法。MeSR由经验丰富的专业人员操作，效率高 建立了技术监督、控制和监测仪器调度和访问、数据的机制 存档和分析、质量控制和质量保证。实验室有足够的容量容纳 由UHC研究计划发起的新研究；研究人员经常有效地利用这些设施 需要新方法开发、初步可行性研究和化验验证。